SVRA compared with GLUE: revenue, margins and what each company keeps, and the suppliers and customers both name

SVRASavara Inc

Mkt capRevenueRevenue

GLUEMonte Rosa Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

SVRASavara Inc

GLUEMonte Rosa Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Supply-chain overlap

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only SVRA 7

—FUJIFILM Diosynth Biotechnologiesunlistedsupplier

—GEMA Biotechunlistedsupplier

—Parexelunlistedsupplier

—PARI Pharma GmbHunlistedsupplier

3 more · SVRA chain ›

Shared 0

No disclosed counterparties: GLUE.

Only GLUE 0

None

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

SVRASavara Inc

4.83▲+10.27%· post 4.84

Mkt cap$992.4MRevenue—Revenue—

GLUEMonte Rosa Therapeutics, Inc.

10.57▲+3.09%· post 10.57

ClosedNov 6 '26

Mkt cap$875.9MRevenue$54MQ3 FY26Revenue$124MFY25

Compare

ClosedNov 6 '26

SVRASavara Inc

GLUEMonte Rosa Therapeutics, Inc.

4.83▲+10.27%post 4.84

Price

10.57▲+3.09%post 10.57

$992.4M

Mkt cap

$875.9M

—

Revenue

$54MQ3 FY26

—

Revenue

$124MFY25

SVRA4.83▲+10.27%vsGLUE10.57▲+3.09%ClosedNov 6 '26